Outlook Therapeutics (OTLK) Short Interest Ratio & Short Volume $5.28 +0.05 (+0.96%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Outlook Therapeutics Short Interest DataOutlook Therapeutics (OTLK) has a short interest of 3.23 million shares, representing 21.21% of the float (the number of shares available for trading by the public). This marks a 8.03% increase in short interest from the previous month. The short interest ratio (days to cover) is 12.7, indicating that it would take 12.7 days of the average trading volume of 256,813 shares to cover all short positions.Current Short Interest3,230,000 sharesPrevious Short Interest2,990,000 sharesChange Vs. Previous Month+8.03%Dollar Volume Sold Short$18.60 millionShort Interest Ratio12.7 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares23,660,000 sharesFloat Size15,230,000 sharesShort Percent of Float21.21%Today's Trading Volume145,169 sharesAverage Trading Volume256,813 sharesToday's Volume Vs. Average57% Short Selling Outlook Therapeutics? Sign up to receive the latest short interest report for Outlook Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartOTLK Short Interest Over TimeOTLK Days to Cover Over TimeOTLK Percentage of Float Shorted Over Time Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Outlook Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20243,230,000 shares $18.60 million +8.0%21.2%12.7 $5.76 10/15/20242,990,000 shares $15.31 million +1.4%19.6%12.2 $5.12 9/30/20242,950,000 shares $15.75 million +19.4%19.4%13.2 $5.34 9/15/20242,470,000 shares $15.98 million +1.7%16.2%10.8 $6.47 8/31/20242,430,000 shares $17.86 million No Change15.9%12 $7.35 8/15/20242,430,000 shares $18.66 million +4.7%16.0%11.5 $7.68 Get the Latest News and Ratings for OTLK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20242,320,000 shares $17.98 million +8.4%15.5%9.8 $7.75 7/15/20242,140,000 shares $18.08 million +9.7%14.3%9 $8.45 6/30/20241,950,000 shares $14.39 million +18.2%13.0%7.8 $7.38 6/15/20241,650,000 shares $12.66 million -0.6%9.7%4.8 $7.67 5/31/20241,660,000 shares $11.74 million +24.8%10.0%2.4 $7.07 5/15/20241,330,000 shares $9.88 million +5.6%8.0%2 $7.43 4/30/20241,260,000 shares $11.24 million +11.5%7.7%2 $8.92 4/15/20241,130,000 shares $9.74 million -15.0%7.4%1.8 $8.62 3/31/20241,330,000 shares $15.88 million +69.4%6.2%2.2 $11.94 3/15/2024785,300 shares $6.47 million -93.3%10.6%1.6 $8.24 2/29/202411,640,000 shares $5.08 million -11.8%7.9%6 $0.44 2/15/202413,200,000 shares $6.40 million -2.7%9.0%6.5 $0.48 1/31/202413,570,000 shares $5.24 million +11.9%9.2%5.9 $0.39 1/15/202412,130,000 shares $4.47 million +7.3%9.2%1.9 $0.37 12/31/202311,310,000 shares $4.46 million +3.3%8.6%1.6 $0.39 12/15/202310,950,000 shares $4.20 million -32.1%8.3%1.5 $0.38 11/30/202316,130,000 shares $7.74 million -21.5%12.2%2.1 $0.48 11/15/202320,540,000 shares $9.16 million -35.9%16.0%1.8 $0.45 10/31/202332,030,000 shares $19.22 million +9.4%25.0%2.8 $0.60 10/15/202329,270,000 shares $9.51 million +9.5%22.9%3.2 $0.33 9/30/202326,720,000 shares $5.91 million +3.4%20.9%4.5 $0.22 9/15/202325,850,000 shares $5.56 million -3.0%20.2%4.6 $0.22 8/31/202326,660,000 shares $6.08 million +52.3%21.1%5.2 $0.23 8/15/202317,510,000 shares $27.14 million +4.9%13.9%12.2 $1.55 7/31/202316,700,000 shares $28.89 million +1.8%13.4%13.1 $1.73 7/15/202316,410,000 shares $27.08 million -2.2%13.2%13.2 $1.65 6/30/202316,770,000 shares $29.18 million -1.9%13.5%15.2 $1.74 6/15/202317,100,000 shares $30.44 million +3.9%13.7%16.6 $1.78 5/31/202316,460,000 shares $24.69 million +0.6%13.2%19.1 $1.50 5/15/202316,370,000 shares $19.64 million -3.1%13.1%24.5 $1.20 4/30/202316,890,000 shares $17.73 million +0.6%13.6%28.6 $1.05 4/15/202316,790,000 shares $18.13 million +2.2%13.6%29.7 $1.08 3/31/202316,430,000 shares $17.91 million +6.1%13.3%27.6 $1.09 3/15/202315,490,000 shares $15.64 million +2.9%12.5%24.9 $1.01Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. 2/28/202315,050,000 shares $16.40 million -1.4%12.2%27.1 $1.09 2/15/202315,270,000 shares $17.71 million -2.9%12.4%29 $1.16 1/31/202315,730,000 shares $18.09 million +3.8%11.7%32 $1.15 1/15/202315,150,000 shares $20.45 million -5.4%12.7%30.2 $1.35 12/30/202216,020,000 shares $17.30 million +0.4%33.0%36.9 $1.08 12/15/202215,960,000 shares $14.37 million -1.1%12.1%34.6 $0.90 11/30/202216,130,000 shares $16.78 million -1.7%12.2%35.1 $1.04 11/15/202216,400,000 shares $17.38 million +3.0%12.4%34.7 $1.06 10/31/202215,930,000 shares $18.48 million +3.6%12.0%33.8 $1.16 10/15/202215,380,000 shares $18.46 million +6.7%11.6%33.4 $1.20 9/30/202214,420,000 shares $17.59 million +5.6%10.9%30.8 $1.22 9/15/202213,660,000 shares $15.71 million +9.2%10.3%29.1 $1.15 8/31/202212,510,000 shares $14.01 million +2.6%9.4%26.3 $1.12 8/15/202212,190,000 shares $15.36 million -0.7%9.2%13.9 $1.26 7/31/202212,280,000 shares $13.88 million +4.0%9.3%12.9 $1.13 7/15/202211,810,000 shares $13.82 million +5.7%8.9%12.2 $1.17 6/30/202211,170,000 shares $11.39 million +4.7%8.4%11 $1.02 6/15/202210,670,000 shares $10.59 million -8.3%6.5%9 $0.99 5/31/202211,640,000 shares $13.39 million +4.2%7.1%8.3 $1.15 5/15/202211,170,000 shares $17.87 million +4.6%6.8%9.3 $1.60 4/30/202210,680,000 shares $16.55 million +1.0%6.5%8.7 $1.55 4/15/202210,580,000 shares $19.26 million +9.3%9.9%7.6 $1.82 3/31/20229,680,000 shares $17.23 million +48.9%N/A6.5 $1.78 3/15/20226,500,000 shares $11.51 million +8.5%N/A4.6 $1.77 2/28/20225,990,000 shares $9.76 million +9.3%4.9%4.5 $1.63 2/15/20225,480,000 shares $7.67 million +3.4%4.5%3.4 $1.40 1/31/20225,300,000 shares $7.53 million +25.0%4.4%3.2 $1.42 1/15/20224,240,000 shares $5.64 million -1.9%3.5%2.8 $1.33 12/31/20214,320,000 shares $5.88 million +0.9%3.5%3.2 $1.36 12/15/20214,280,000 shares $6.21 million +16.3%3.5%3.2 $1.45 11/30/20213,680,000 shares $5.56 million -41.6%4.0%2.8 $1.51 11/15/20216,300,000 shares $12.29 million -1.4%7.1%5.7 $1.95 10/29/20216,390,000 shares $13.23 million +8.7%7.2%7.1 $2.07 10/15/20215,880,000 shares $12.41 million -3.5%6.7%2 $2.11 9/30/20216,090,000 shares $13.22 million +8.2%6.9%2.1 $2.17 9/15/20215,630,000 shares $13.62 million -0.5%6.4%1.8 $2.42 8/31/20215,660,000 shares $15.62 million +1.4%6.4%1.8 $2.76 8/13/20215,580,000 shares $13.39 million +71.7%6.3%1.8 $2.40 7/30/20213,250,000 shares $7.35 million +3.2%3.7%1.1 $2.26 7/15/20213,150,000 shares $7.15 million -25.2%3.6%3.4 $2.27 6/30/20214,210,000 shares $10.48 million +214.2%4.8%4.2 $2.49 6/15/20211,340,000 shares $3.46 million +6.4%1.5%1.5 $2.58 5/28/20211,260,000 shares $3.38 million +15.6%1.4%1.3 $2.68 5/14/20211,090,000 shares $2.11 million +41.8%N/A1 $1.94 4/30/2021768,600 shares $1.79 million +155.3%N/A0.3 $2.33 4/15/2021301,100 shares $563,057.00 -34.1%N/A0.1 $1.87 3/31/2021457,100 shares $996,478.00 +30.8%N/A0.1 $2.18 3/15/2021349,500 shares $782,880.00 +20.8%N/A0.1 $2.24 2/26/2021289,400 shares $616,422.00 -67.3%N/A0.1 $2.13 2/12/2021884,100 shares $2.29 million -55.1%N/A0.2 $2.59Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. 1/29/20211,970,000 shares $2.40 million +25.5%N/A0.5 $1.22 1/15/20211,570,000 shares $1.93 million -19.9%N/A1.8 $1.23 12/31/20201,960,000 shares $2.61 million -2.5%N/A2.1 $1.33 12/15/20202,010,000 shares $2.65 million -3.4%N/A2.3 $1.32 11/30/20202,080,000 shares $2.56 million -25.2%N/A2.3 $1.23 11/15/20202,780,000 shares $2.89 million -13.9%N/A1.7 $1.04 10/30/20203,230,000 shares $2.60 million +4.5%N/A1.7 $0.81 10/15/20203,090,000 shares $2.70 million +8.8%N/A1.4 $0.87 9/30/20202,840,000 shares $2.04 million +16.9%N/A1.1 $0.72 9/15/20202,430,000 shares $1.56 million -9.3%N/A0.8 $0.64 8/31/20202,680,000 shares $1.77 million +0.4%N/A0.7 $0.66 8/14/20202,670,000 shares $3.74 million +29.6%N/A0.8 $1.40 7/31/20202,060,000 shares $2.80 million -11.6%N/A0.7 $1.36 7/15/20202,330,000 shares $3.22 million +8.9%N/A0.8 $1.38 6/30/20202,140,000 shares $2.76 million -23.3%8.2%0.9 $1.29 6/15/20202,790,000 shares $3.12 million +29.8%14.3%1.6 $1.12 5/29/20202,150,000 shares $2.19 million +1.4%N/A2.1 $1.02 5/15/20202,120,000 shares $1.52 million -1.4%N/A2.8 $0.72 4/30/20202,150,000 shares $1.48 million -0.9%N/A4.1 $0.69 4/15/20202,170,000 shares $1.54 million -1.8%N/A4.1 $0.71 3/31/20202,210,000 shares $1.48 million +5.4%N/A4 $0.67 3/13/20202,097,400 shares $1.30 million +1.8%N/A5.6 $0.62 2/28/20202,060,000 shares $1.13 million -5.1%N/A2.2 $0.55 2/14/20202,170,000 shares $1.52 million +5.9%18.0%2 $0.70 1/31/20202,050,000 shares $1.60 million -21.2%17.0%2 $0.78 1/15/20202,600,000 shares $2.68 million +30.0%21.4%2.7 $1.03 12/31/20192,000,000 shares $2.08 million +13.6%18.3%2.3 $1.04 OTLK Short Interest - Frequently Asked Questions What is Outlook Therapeutics' current short interest? Short interest is the volume of Outlook Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, investors have sold 3,230,000 shares of OTLK short. 21.21% of Outlook Therapeutics' shares are currently sold short. Learn More on Outlook Therapeutics' current short interest. What is a good short interest ratio for Outlook Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OTLK shares currently have a short interest ratio of 13.0. Learn More on Outlook Therapeutics's short interest ratio. What is a good short interest percentage for Outlook Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 21.21% of Outlook Therapeutics' floating shares are currently sold short. Is Outlook Therapeutics' short interest increasing or decreasing? Outlook Therapeutics saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 3,230,000 shares, an increase of 8.0% from the previous total of 2,990,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Outlook Therapeutics' float size? Outlook Therapeutics currently has issued a total of 23,660,000 shares. Some of Outlook Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Outlook Therapeutics currently has a public float of 15,230,000 shares. How does Outlook Therapeutics' short interest compare to its competitors? 21.21% of Outlook Therapeutics' shares are currently sold short. Here is how the short interest of companies compare to Outlook Therapeutics: Coherus BioSciences, Inc. (27.35%), Champions Oncology, Inc. (3.22%), Protara Therapeutics, Inc. (13.28%), Zevra Therapeutics, Inc. (7.53%), ProKidney Corp. (13.64%), REGENXBIO Inc. (9.91%), Terns Pharmaceuticals, Inc. (7.17%), Esperion Therapeutics, Inc. (17.16%), Y-mAbs Therapeutics, Inc. (10.84%), Xeris Biopharma Holdings, Inc. (7.63%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Outlook Therapeutics stock? Short selling OTLK is an investing strategy that aims to generate trading profit from Outlook Therapeutics as its price is falling. OTLK shares are trading up $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Outlook Therapeutics? A short squeeze for Outlook Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of OTLK, which in turn drives the price of the stock up even further. How often is Outlook Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OTLK, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Coherus BioSciences Short Interest Data Champions Oncology Short Interest Data Protara Therapeutics Short Interest Data Mereo BioPharma Group Short Interest Data Arcturus Therapeutics Short Interest Data Y-mAbs Therapeutics Short Interest Data Zevra Therapeutics Short Interest Data ProKidney Short Interest Data Esperion Therapeutics Short Interest Data REGENXBIO Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OTLK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OTLK Stock Alerts